期刊文献+

雷公藤多苷对特发性膜性肾病患者抗磷脂酶A2受体抗体的影响 被引量:8

Effect of Multi-glycosides of Tripterygium Wilfordii in the Treatment of Idiopathic Membranous Nephropathy Anti-Phospholipase A2 Receptors
下载PDF
导出
摘要 目的:观察雷公藤多苷治疗特发性膜性肾病并探讨其对抗磷脂酶A2受体抗体(Anti-PLA2R)的影响。方法:选取2014年6月至2016年6月前来肾内科门诊及住院部就诊的特发性膜性肾病患者,共68例。所有入选者均通过随机数字表法分为观察组和对照组,2组均进行基础对症治疗,对照组加泼尼松联合环磷酰胺(CTX)治疗,观察组加口服雷公藤多苷片治疗,共治疗12周。所有患者均在于治疗前、治疗后第12周进行24 h尿蛋白定量、血清白蛋白(ALB)、血尿素氮(BUN)、血清肌酐(SCr)、血清PLA2R表达进行评价。结果:经过12周的治疗后,通过检测在治疗前后患者的24 h尿蛋白定量、BUN、CREA均明显有下降(P<0.05),但2组比较,差异无统计学意义(P>0.05);在治疗后2组ALB均明显升高,与治疗前相比,差异有统计学意义(P<0.05),但2组比较,差异无统计学意义(P>0.05);2组血清Anti-PLA2R的表达在治疗后均得到明显降低,且观察组明显优于对照组(P<0.05)。结论:雷公藤多苷片与泼尼松联合环磷酰胺疗效相当,可有效改善特发性膜性肾病患者的肾功能,减轻患者临床症状及体征;且雷公藤多苷片不良反应较少。 Objective:To observe the effects of multi-glycosides of triptery-gium wilfordii in the treatment of idiopathic menlbranous nephropathy, and to explore the effects on anti-phospholipase A2 receptors (Anti-PLA2R). Methods:A total of 68 patients with idiopathic membranous nephropathy in our hospital from November 2013 to December 2015 were selected and randomly divided into observation group and control group by random number table. Two groups of patients were given primary symptomatic treatment. The control group was given prednisone and cyclophosphamide, and the treatment group was treated with oral administration of multi-glycosides of triptery-gium wilfordii. The treatment last for 12 weeks. 24h urinary protein, serum albumin (ALB) , blood urea nitrogen ( BUN), serum creatinine (SCr), serum PLA2R expression of all patients before treatment, and 12 weeks after treatment were evaluated. Results:After 12 weeks of treatment, 24h urine protein, BUN, CREA of patients were significantly decreased af-ter treatment ( P 〈 0. 05 ), but there was no significant difference between treatment group and control group ( P 〈 0. 05 ). After treatment, ALB of both groups was significantly increased. Compared with before treatment, there was statistically significant difference ( P 〈 0. 05 ), but there was no significant difference between two groups ( P 〈 0. 05 ). The expression of serum Anti PLA2R of two groups was significantly decreased after treatment, and the treatment groups was significantly better than the control group ( P 〈 0. 05 ). Conclusion : Multi-glycosides of triptery-gium wilfordii has similar efficacy with prednisone combined with cy-clophosphamide, which can effectively improve renal function of patients with idiopathic membranous nephropathy, relieve clinical swnDtoms and signs. Multi-glvcosides of triDtervgium wilfordii has less side effects, and is worthy of clinical research.
作者 余霄 欧阳晓琴 姜宝霞 舒亚君 Yu Xiao;Ouyang Xiaoqin;Jiang Baoxia;Shu Yajun(Department of Nephrology,Chongqing Hospital of Traditional Chinese Medicine,Chongqing 400021,China)
出处 《世界中医药》 CAS 2018年第5期1168-1171,共4页 World Chinese Medicine
基金 重庆市卫生和计生委中医药科技项目(2Y20150235)
关键词 雷公藤多苷 特发性膜性肾病 磷脂酶 A2 受体抗体 Multi-glycosides of triptery-gium wilfordii Idiopathic menlbranous nephropathy Phospholipase A2 receptor antibody
  • 相关文献

参考文献6

二级参考文献73

  • 1侯静,曹灵,刘进,陈昕.特发性膜性肾病的免疫抑制疗法的系统综述与meta分析[J].中国生化药物杂志,2014,34(5):74-78. 被引量:6
  • 2林绥,于贤勇,阙慧卿,陈忠,谢狄霖,李援朝.雷公藤中的二萜内酯类成分[J].药学学报,2005,40(7):632-635. 被引量:13
  • 3Quaglia M,Stratta P. Idiopathic membranous nephropathy : manage.ment strategies [J]. Drugs ,2009,69 (10) :1303-1317.
  • 4Cameron JS,Healy MJ,Adu D. The Medical Research Council trialof short-term high-dose alternate day prednisolone in idiopathicmembranous nephropathy with nephritic syndrome in adults. TheMRC Glomerulonephritis Working Party[J]. Q J Med, 1990,74(274):133-156.
  • 5Ponticelli C,Zucchelli P,Passerini P,e. al. A 10-year follow-up of arandomized study with methylprednisolone and chlorambueii inmembranous nephropathy[J]. Kidney Int, 1995,48(5) :1600-1604.
  • 6Howman A,Chapman TL,Tangdon MM,et al. Immunosuppressionfor progressive membranous nephropathy: a UK randomised con-trolled trial[J]. Lancet,2013,381 .9868) :744-751.
  • 7Ponticelli C,Altieri P,Scolari Y,et al. A randomized study compa-ring methylprednisolone plus chlorambucil versus methylprednisolo-ne plus cyclophosphamide in idiopathic membranous nephropathy[J]. J Am Soc Nephrol, 1998,9(3) :444-450.
  • 8du Buf-Vereijken PW, Branten AJ, Wetzels JF, et al. Cytotoxictherapy for membranous nephropathy and renal insufficiency :improved renal survival but high relapse rate [J]. Nephrol DialTransplant,2004,19(5) : 1142-1148.
  • 9Jha V,Ganguli A,Saha TK,ef al. A randomized,controlled trial ofsteroids and cyclophosphamide in adults with nephritic syndromecaused by idiopathic membranous nephropathy [J]. J Am SocNephrol,2007,18(6) : 1899-1904.
  • 10Naumovic R, Jovanovic D, Pavlovic S, et al. Cyclosporine versusazathioprine therapy in high-risk idiopathic membranous nephropa-thy patients: A 3-year prospective study[J]. Biomed Phannacoth-er,2011,65(2) :105-110.

共引文献66

同被引文献156

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部